Susan O’Brien

3.0k citations

24 papers · 2.2k indexed · h-index 15

Genetics top 0.5%
Hematology top 1%
Pathology and Forensic Medicine top 1%
Immunology top 5%
Public Health, Environmental and Occupational Health top 5%

Co-authors: Hagop M. Kantarjian Michael J. Keating Jörge E. Cortes Kim‐Anh Do Maher Albitar Susan Lerner Deborah A. Thomas Stefan Faderl
Topics: Chronic Lymphocytic Leukemia Research (12 papers)Chronic Myeloid Leukemia Treatments (10 papers)Acute Lymphoblastic Leukemia research (6 papers)
Cited by: Genetics Hematology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology Blood Cancer
Partner nations: United States

In The Last Decade

Susan O’Brien

24 papers receiving 2.1k citations

Peers

Countries citing papers authored by Susan O’Brien

Since Specialization

Citations

This map shows the geographic impact of Susan O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan O’Brien more than expected).

Fields of papers citing papers by Susan O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan O’Brien. The network helps show where Susan O’Brien may publish in the future.

Co-authorship network of co-authors of Susan O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Susan O’Brien. A scholar is included among the top collaborators of Susan O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan O’Brien. Susan O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia 2024 ·Leukemia & lymphoma ·(unknown),(unknown),Hagop M. Kantarjian,David McCue,Fadi Haddad,William G. Wierda,Alessandra Ferrajoli,Jan A. Burger,(unknown),Jeffrey L. Jorgensen,Sa A. Wang,Keyur Patel,Sanam Loghavi,Susan O’Brien,Farhad Ravandi	4
2	The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia 2015 ·Expert Review of Anticancer Therapy ·David Sanford,Hagop M. Kantarjian,Susan O’Brien,Elias Jabbour,Jörge E. Cortes,Farhad Ravandi	12
3	Ibrutinib: a paradigm shift in management of CLL 2014 ·Expert Review of Hematology ·Talha Badar,Jan A. Burger,William G. Wierda,Susan O’Brien	11
4	Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia 2013 ·Hematology/Oncology Clinics of North America ·Nitin Jain,Susan O’Brien	12
5	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience 2013 ·Leukemia & lymphoma ·Ohad Benjamini,Hagop M. Kantarjian,Mary Beth Rios,Elias Jabbour,Susan O’Brien,Preetesh Jain,Marylou Cárdenas-Turanzas,Stefan Faderl,Guillermo Garcia‐Manero,Farhad Ravandi,Gautam Borthakur,Alfonso Quintás‐Cardama,Jörge E. Cortes	32
6	Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study 2012 ·The Lancet Oncology ·Hagop M. Kantarjian,Deborah A. Thomas,Jeffrey L. Jorgensen,Elias Jabbour,Partow Kebriaei,Michael Rytting,Sergernne York,Farhad Ravandi,Monica Kwari,Stefan Faderl,Mary Beth Rios,Jörge E. Cortes,Luis Fayad,(unknown),Sa A. Wang,Richard Champlin,Anjali S. Advani,Susan O’Brien	309
7	Aspergillus pseudomembranous necrotizing tracheitis 2012 ·American Journal of Hematology ·Xiuning Le,Preetesh Jain,Susan O’Brien	2
8	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes 2011 ·Biology of Blood and Marrow Transplantation ·Partow Kebriaei,Rima M. Saliba,Gabriela Rondón,(unknown),Rajyalakshmi Luthra,Paolo Anderlini,Börje S. Andersson,Elizabeth J. Shpall,Uday Popat,Roy B. Jones,Laura L. Worth,Farhad Ravandi,Deborah A. Thomas,Susan O’Brien,Hagop M. Kantarjian,M. Lima,Sergio Giralt,Richard E. Champlin	50
9	The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells 2010 ·Investigational New Drugs ·(unknown),Zeev Estrov,Yongtao Wang,Susan O’Brien,Stefan Faderl,David Harris,(unknown),Inbal Hazan‐Halevy,Zhiming Liu,Patricia E. Koch,Hagop Kantarjian,Michael J. Keating,Alessandra Ferrajoli	12
10	Chronic Myelogenous Leukemia 2009 ·Journal of the National Comprehensive Cancer Network ·Susan O’Brien,Ellin Berman,Hossein Borghaei,Daniel J. DeAngelo,Marcel P. Devetten,Steven M. Devine,Harry P. Erba,Jason Gotlib,Madan Jagasia,Joseph O. Moore,Tariq I. Mughal,Javier Pinilla‐Ibarz,Jerald P. Radich,Neil P. Shah,Paul J. Shami,Benjamin D. Smith,David S. Snyder,Martin S. Tallman,Moshe Talpaz,Meir Wetzler	175
11	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse 2009 ·Leukemia Research ·Farhad Ravandi,Hagop M. Kantarjian,Stefan Faderl,Guillermo Garcia‐Manero,Susan O’Brien,Charles Koller,Sherry Pierce,Mark Brandt,Deborah D. Kennedy,Jörge E. Cortes,Miloslav Beran	97
12	Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation 2001 ·Biology of Blood and Marrow Transplantation ·Avichai Shimoni,James Gajewski,Michele Donato,Thomas G. Martin,Susan O’Brien,Moshe Talpaz,(unknown),Martin Körbling,R. Champlin,Sergio Giralt	48
13	CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia 2001 ·Blood ·Sherif Ibrahim,Michael J. Keating,Kim‐Anh Do,Susan O’Brien,Yang O. Huh,Iman Jilani,Susan Lerner,Hagop M. Kantarjian,Maher Albitar	335
14	Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia 2000 ·Journal of Clinical Oncology ·Hagop M. Kantarjian,Moshe Talpaz,Terry L. Smith,Jörge E. Cortes,Francis J. Giles,Mary Beth Rios,(unknown),James Gajewski,Anthony J. Murgo,Bruce D. Cheson,Susan O’Brien	71
15	Primary refractory and relapsed adult acute lymphoblastic leukemia 1999 ·Cancer ·Deborah A. Thomas,Hagop M. Kantarjian,Terry L. Smith,Charles Koller,Jörge E. Cortes,Susan O’Brien,Francis J. Giles,James Gajewski,Sherry Pierce,Michael J. Keating	144
16	Activity of Oral and Intravenous 9-Aminocamptothecin in SCID Mice Engrafted with Human Leukemia 1998 ·Leukemia & lymphoma ·Sima Jeha,Hagop M. Kantarjian,Susan O’Brien,(unknown),Miloslav Beran	11
17	Relapse of acute myelogenous leukemia during low dose lnterleukin-2 (IL-2) Therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain 1995 ·Cancer ·Karsten Spiekermann,Susan O’Brien,(unknown)	5
18	Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis 1993 ·The American Journal of Medicine ·(unknown),H. Kantarjian,Moshe Talpaz,Susan O’Brien,Ann Cork,Elihu H. Estey,Sherry Pierce,Michael Keating	74
19	Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes 1991 ·British Journal of Haematology ·Elihu H. Estey,Razelle Kurzrock,Moshe Talpaz,K. B. McCredie,Susan O’Brien,(unknown),Michael J. Keating,(unknown),(unknown)	56
20	Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia 1991 ·Cancer ·Susan O’Brien,(unknown),Elihu H. Estey,Charles Koller,Miloslav Beran,Kenneth B. McCredie,Michael A. Keating	19

About Susan O’Brien

Susan O’Brien is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 24 papers that have together received 2.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Acute Lymphoblastic Leukemia research (6 papers). The work is most often cited by research in Genetics (1.4k citations), Hematology (997 citations) and Pathology and Forensic Medicine (933 citations). Susan O’Brien has collaborated with scholars based in United States. Frequent co-authors include Hagop M. Kantarjian, Michael J. Keating, Jörge E. Cortes, Kim‐Anh Do, Maher Albitar, Susan Lerner, Deborah A. Thomas, Stefan Faderl, Charles Koller and William G. Wierda. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact